<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00254137</url>
  </required_header>
  <id_info>
    <org_study_id>CRC-02-2004</org_study_id>
    <nct_id>NCT00254137</nct_id>
  </id_info>
  <brief_title>Cap/Iri Plus Cetuximab Compared to Cap/ox Plus Cetuximab in Patients With Metastatic Colorectal Cancer.</brief_title>
  <official_title>A Randomized Phase II-study to Evaluate the Safety and Efficacy of Capecitabine Plus Irinotecan Plus Cetuximab Compared to Capecitabine Plus Oxaliplatin Plus Cetuximab in First-line Treatment of Patients With Metastatic Colorectal Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ludwig-Maximilians - University of Munich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ludwig-Maximilians - University of Munich</source>
  <brief_summary>
    <textblock>
      A randomized phase II-study to evaluate the safety and efficacy of capecitabine plus
      irinotecan plus cetuximab compared to capecitabine plus oxaliplatin plus cetuximab in
      first-line treatment of patients with metastatic colorectal cancer.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2004</start_date>
  <completion_date>November 2006</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate (CR+PR)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to progression.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (CR+PR+SD).</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety profile.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grade 3/4- toxicities.</measure>
  </secondary_outcome>
  <enrollment>92</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>capecitabine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>irinotecan</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxaliplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cetuximab</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed metastatic colorectal cancer.

          -  EGF-receptor testing.

          -  No prior chemotherapy for colorectal cancer (except adjuvant chemotherapy with an
             interval ³ 6 months).

          -  No prior therapy with topoisomerase-1 inhibitors, no prior therapy directed against
             the EGF-pathway.

          -  No prior surgery (except diagnostic biopsy) or radiation therapy 4 weeks before start
             of study treatment.

          -  Measurable disease (diameter ³ 20mm, diameter ³ 10mm with spiral-CT).

          -  Male and female patients ³ 18 years, £ 75 years. Karnofsky PS ³ 70%. Life expectancy ³
             3 months. Effective contraception if risk of conception exists.

          -  Adequate bone marrow, liver and renal function (leucocytes ³3.000/µl, neutrophils
             ³1.500/µl, platelets ³100.000/µl, hemoglobin ³9g/dl, bilirubin £1,5x ULN, ASAT and
             ALAT £3x ULN (£5x ULN with liver metastasis), serum creatinine £1,5x ULN).

          -  Written informed consent.

        Exclusion Criteria:

          -  Concurrent treatment of colorectal cancer (except study medication).

          -  EGF-receptor testing not possible.

          -  Known DPD-deficiency (no particular screening necessary). Known
             Gilbert-Meulengracht-Syndrome (no particular screening necessary).

          -  Known or expected contraindication against study medication.

          -  Participation in other studies during 30 days before study entry.

          -  Prior myocardial infarction, severe renal insufficiency (creatinine clearance
             £30ml/min).

          -  Previous malignancy (except colorectal cancer, history of basal cell carcinoma of skin
             or pre-invasive carcinoma of the cervix with adequate treatment and no sign of disease
             during 5 years).

          -  Known or suspected cerebral metastasis.

          -  History of inflammatory bowel disease. Symptomatic peritoneal carcinomatosis.

          -  Drug or alcohol abuse. Lack of adequate legal capacity.

          -  Breast-feeding or pregnant women.

          -  Concurrent medication with Sorivudine and analoga, anticoagulation with Cumarine or
             derivatives.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Volker Heinemann, PhD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Munich - Klinikum Grosshadern</affiliation>
  </overall_official>
  <verification_date>September 2004</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 14, 2005</study_first_submitted>
  <study_first_submitted_qc>November 14, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 15, 2005</study_first_posted>
  <last_update_submitted>October 27, 2010</last_update_submitted>
  <last_update_submitted_qc>October 27, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 28, 2010</last_update_posted>
  <keyword>capecitabine</keyword>
  <keyword>irinotecan</keyword>
  <keyword>cetuximab</keyword>
  <keyword>oxaliplatin</keyword>
  <keyword>colorectal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

